Alterations in DNA methylation have been observed in PRCC and are associated with tumor stage and clinical prognosis. 4 RASSF1A is frequently hypermethylated, with less prevalent hypermethylation of APC, CDH1, and GSTP1. 5 Moreover, CDH1 methylation is linked to pathologic stage and patient survival. 5 The Cancer Genome Atlas (TCGA)
Research Network reports distinct DNA methylation patterns between type 1 and type 2 PRCC. 1 Furthermore, type 2 is further stratified into three subgroups based on multiplatform omics analysis (copy number, DNA methylation, gene expression, miRNA expression, and protein expression). Each of the three type 2 PRCC subgroups display differential methylation patterns, one linked to a CpG island methylator phenotype (CIMP) phenotype and the other two each showing distinct DNA methylation clusters (cluster 1 & 2) through genome-wide profiling based on the Illumina Infinium HumanMethylation450k array (450k, TCGA-KIRP project). While PRCC comprises 15%-20% of all RCCs, the overwhelming majority of analyses are focused on the most frequent subtype, clear cell RCC, leaving a gap in knowledge for PRCC etiology, especially at the epigenetic level. To address this issue, we examine 450k data from TCGA's KIRP dataset with a specific focus on identifying DNA methylation alterations and copy number variations (CNVs) that can be linked specifically to advanced-stage PRCC. Our analysis reveals that key regulatory regions (CpG islands, promoters, and enhancers) are dominated by hypermethylation events, with relatively fewer DNA hypomethylation events distinguishing advanced-stage PRCC. Due to the reversibility of DNA methylation, coupled with the limited treatment options available for PRCC, we sought to identify novel therapeutic targets and epigenetic markers for PRCC. To that end, we identify a subset of CpGs (cg00489401, cg27649239, cg20555674, and cg07196505) and a CNV (PTK7 amplification) that differentiate localized from advanced-stage type 2 PRCC, demonstrating that both genetic and epigenetic features likely contribute to disease progression.
| MATERIALS AND METHODS

| The Cancer Genome Atlas (TCGA) data
TCGA-KIRP 450k array data were downloaded from theGenomic Data Commons (GDC) (https ://gdc-portal.nci. nih.gov/legacy-archi ve/searc h/f). Ten patients were reclassified based on review by a group of expert pathologists, as described in the TCGA-KIRP publication. 1 We utilize the reclassified type 1 and type 2 data in this analysis: eight patients (TCGA-AL-7173, TCGA-B1-A47M, TCGA-B9-7268, TCGA-BQ-7060, TCGA-BQ-7062, TCGA-EV-5901, TCGA-HE-A5NI, and TCGA-PJ-A5Z8) are   reclassified as type 1 while two patients (TCGA-A4-8098 and TCGA-J7-8537) are reclassified as type 2.
| 450k array data analysis
Raw data from the 450k array are normalized by the Subset-quantile Within Array Normalization (SWAN) using the R package "RnBeads" (version 1.6.1). 6 After filtering out CpGs on allosomes (leaving 473 921 CpGs) and adjusting for age and gender, differentially methylated probes (DMP) are defined as having a change in methylation (delta beta)> |0.1| and a false discovery rate (FDR) adjusted P value < 0.05.
| Ingenuity pathway analysis
Pathways are identified and analyzed using Ingenuity Pathway Analysis (IPA, http://www.qiagen.com/ingen uity). The significance of genes in each pathway is determined using a right-tailed Fisher's exact test. The top five significant pathways in each comparison are selected for presentation.
| Marker analysis
For classification with the nearest shrunken centroid method, the R package "pamr" (version 1.48.0) is used. 7 After 10-fold cross validation and setting the shrinkage threshold to 5.404, a list of CpGs capable of discriminating between localized and advanced-stage type 2 PRCC is generated. CpGs that progressively gain or lose methylation from localized to advanced-stage type 2 PRCC are defined using the R package "pROC" (version 1.14.0) to perform receiver operating characteristic (ROC) analysis for a multivariable logistic regression model. 
| Copy number analysis
The R package "ChAMP" (version 1.8.2) is used to analyze copy number aberrations using IDAT data from the 450K array. 9 Data are linked to genes using the R package "CNTools" (version 1.26.0). 10 Genes are considered significantly altered if the segment mean value is > |0.2| and more than 20% of samples are affected with FDR < 0.05.
| Survival analysis
Kaplan-Meier survival curves are calculated and plotted in R using the "survplot" function of the "rms" package.
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(version 4.5-0). 9 The log rank test is used to compare the survival differences between the groups; P < 0.05 is regarded as significant. Figure 1A ,B) when comparing advanced to localized stages. These alterations are also stepwise in nature from adjacent-normal to localized to advanced stage ( Figure 1C,D From localized to advanced-stage, the majority of progressive hypermethylation changes occur at promoters (including TSS1500, TSS200, and 5′-UTR) and first exon regions, while progressive hypomethylation changes are evenly distributed across intragenic regions ( Figure 2A ). Furthermore, progressive gains of methylation are mostly localized at or adjacent to CpG islands, while progressive loss events occur primarily outside of CpG islands ( Figure 2B ). Differentially methylated region (DMR) analysis shows that progressive hypermethylation is distributed at reprogramming-specific differentially methylated regions (rDMR), cancer-specific differentially methylated regions (cDMR), or other DMRs genome-wide, while progressive hypomethylation is primarily localized to cDMRs ( Figure  2C ). 13 More enhancers (1.2%) progressively gain methylation than lose methylation (0.4%, Figure 2D ). While 1620 genes (from 848 gene promoter regions) progressively gain methylation, 442 genes (from 206 gene promoter regions) progressively lose DNA methylation ( Figure 2E ). Taken together, these findings indicate that DNA hypermethylation, particularly at gene regulatory elements, is the dominant change occurring during the progression of PRCC from early to advanced stage.
| Functional analysis of genes undergoing progressive DNA methylation changes from localized to advanced-stage type 2 PRCC
To investigate the potential functional consequences of DNA methylation changes that occur between localized and advanced-stages, pathway analysis was performed for genes linked to progressively hyper-or hypomethylated CpGs located within gene promoters. Finally, 848 genes corresponding to 1419 CpGs with progressive promoter hypermethylation, and 206 genes corresponding to 258 CpGs with progressive promoter hypermethylation were further analyzed. Genes showing progressive promoter hypermethylation are associated with adrenergic signaling, G protein signaling, and Gamma aminobutyric acid (GABA) receptor signaling, while genes with progressive promoter hypomethylation are associated with immune response, cytokine production, and the inflammasome pathway (Tables S2 and S3) . Diseases and disorders analysis shows that the majority of genes with progressive promoter hyper-or hypomethylation are related to cancer. Molecular and cellular functions analysis reveals that differentially methylated loci are associated with cellular development, cellular growth and proliferation, and cell-to-cell signaling and interaction (Tables S2 and S3 ). Altogether, this analysis suggests that DNA methylation alterations have a functional impact on key pathways related to initiation and progression of PRCC. Figure  3A) . Moreover, a model that combines the selected four CpGs yields an area under the ROC curve (AUROC) value of 0.94, suggesting excellent sensitivity and specificity for differentiating between localized and advanced-stage type 2 PRCC ( Figure 3B ). Survival analyses reveal that methylation levels of each of the selected four CpGs correlate significantly with patient survival ( Figure 3C -F, P < 0.05).
| Copy number variation in localized and advanced-stage type 2 PRCC
Copy number analysis based on the raw 450k data, using adjacent-normal tissue as control data, reveals differences between localized and advanced-stage type 2 PRCC ( Figure  4A ,B, (Figure 4C,D) . CNV at SMYD3 has no effect on survival (P = 0.49, data not shown). identified differentially methylated CpGs (cg00489401, cg27649239, cg20555674, and cg07196505) are FLT4, LBXCOR1, ARL5C, and A2BP1, respectively. Only FLT4 is downregulated in localized-stage type 2 PRCC compared with adjacent-normal samples. Expression of the other three genes shows no significant difference between adjacent-normal samples and localized or advanced-stage type 2 PRCC (not shown). Expression of PTK7 is not significantly changed in localized-stage type 2 PRCC when compared to adjacentnormal samples. However, from localized to advancedstage type 2 PRCC, PTK7 is significantly upregulated (logFC = 0.95, FDR = 0.02), suggesting that PTK7 is associated with progression in type 2 PRCC. Moreover, while PTK7 gain mostly occurs in advanced-stage type 2 PRCC, samples with PTK7 gain have higher gene expression than patients without gain in PTK7 (log FC = 1.08, FDR = 0.01). Taken together, these findings reveal several potential genetic-and epigenetic-based markers that could be developed into diagnostic tools to allow for better stratification of patients for clinical management.
| PTK7 is upregulated from localized to advanced-stage type 2 PRCC
| DISCUSSION
The present study identifies a group of CpGs that progressively gain or lose DNA methylation from localized to advanced-stage type 2 PRCC. Four CpGs (cg00489401, cg27649239, cg20555674, and cg07196505) differentiate between stages. Moreover, these four CpGs are associated with patient survival and may also serve as prognostic markers. Copy number analysis reveals that gain of PTK7 occurs most frequently in advanced-stage tumors and predicts poor survival. RNA-seq analysis shows that PTK7 is significantly upregulated in advanced stages, and correlates with copy number gain. Roles for PTK7 in cancer cell invasion have been reported in several clinical and experimental studies, [15] [16] [17] suggesting that PTK7 represents a potential therapeutic target in advanced-stage type 2 PRCC. Relationships between gene body DNA methylation and expression are complex and multifactorial, therefore whether the methylation changes we identified in four loci drive altered expression or splicing will require further investigation. These DMRs may, nonetheless, serve as useful markers of PRCC progression.
Our present study also demonstrates that genes targeted for progressive hypermethylation in the transition to advancedstage from localized PRCC are associated with adrenergic signaling, G protein signaling, and GABA receptor signaling. In the RCC cell line RCC7, acute activation of the β2-adrenergic receptor-regulated cancer cell migration occurs by promoting RhoA activation and influencing focal adhesion formation.
18 G protein-coupled receptors (GPCRs) play critical roles in the invasion and metastasis of cancer cells by activating Rho GTPases, and regulating cytoskeletal remodeling and angiogenesis. In the RCC cell line Caki-2, GABA stimulation promotes cancer cell invasion via ERK1/2-dependent upregulation of MMPs; an effect mediated mainly through the GABA-B receptor. 19 Thus, while DNA methylation changes may serve as prognostic markers in pRCC, they may also functionally influence the underlying biology of the disease. Current recommendations according to the ESMO Clinical Practice Guidelines for RCC state that before treatment with ablative therapies, or in patients with metastatic disease prior to initiating systemic treatment, a renal biopsy should be performed to confirm malignancy. 20 In elderly patients with significant comorbidities or those with a shortlife expectancy and solid renal tumors <4 cm, renal biopsy is also recommended for active surveillance. 20 In addition to clinical and histopathological findings, molecular biomarkers may exert additional benefit for diagnosis and prognosis of type 2 PRCC. In the present study, we identify four DNA methylation markers that distinguish between localized and advanced-stage type 2 PRCC with excellent sensitivity and specificity. Moreover, these four DNA methylation markers may be useful for predicting patient outcome. Because the sample size of type 2 PRCC from TCGA-KIRP is small, we have not divided samples into training and validation sets, thus the differentially methylated sites we identified require validation as part of future studies. In addition, while the DNA methylation markers in our present study were identified from tumor tissue, several reports have demonstrated that blood-or urine-based DNA methylation markers could be useful for noninvasive early diagnosis or prognosis of cancers such as prostate, bladder, colorectal, lung, and breast, 21, 22 highlighting a logical next step for our studies with PRCC. PTK7 is an intrinsic component of the Wnt pathway and a member of the receptor tyrosine kinase family. 23 In multiple cancers including esophageal squamous cell carcinoma, intrahepatic cholangiocarcinoma, breast cancer, and prostate cancer, PTK7 is overexpressed and inversely correlated with overall survival. [24] [25] [26] Copy number gain in PTK7 is associated with increased gene expression, which is also observed in gastric cancer. 27, 28 While located within the top 4% of all regions sustaining copy number gain in an independent lung cancer dataset, PTK7 is also overexpressed in nonsmall cell lung cancers. 29 In vitro experiments demonstrate that PTK7 directs cancer cell motility and invasiveness, indicating that its amplification potentially plays a pro-oncogenic role in driving tumorigenesis and/or metastasis. [24] [25] [26] 30 By analyzing CNV and RNA-seq data, our study shows that PTK7 may serve a prognostic biomarker and a potential treatment target in advanced-stage type 2 PRCC. A phase II study reported that sunitinib, a multi-targeted receptor tyrosine kinase inhibitor, was effective in treating type 1 and 2 metastatic PRCC. 31 As a receptor tyrosine kinase, PTK7 is a predicted target of sunitinib. 32 Therefore, it is possible that the effect of sunitinib in PRCC may be partly mediated through inhibition of PTK7. PF-06647020, an antibody-drug conjugate targeting PTK7, induces sustained tumor regression in patients with triple-negative breast cancer, ovarian cancer, and nonsmall cell lung cancer. 33 Whether PF-06647020 has a similar effect in advanced-stage type 2 PRCC remains to be investigated.
In conclusion, through analysis of 450K methylation data from TCGA-KIRP, we identified four CpGs that may serve as DNA methylation markers for differentiating between localized to advanced-stage type 2 PRCC. Moreover, these four CpGs may also be useful as prognostic markers. CNV analysis reveals that copy number gain in PTK7 is associated with poor survival and higher expression from localized-stage to advanced-stage type 2 PRCC, suggesting that PTK7 represents a promising treatment target for advanced-stage type 2 PRCC.
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